The discovery that reserpine can influence the storage and uptake of the catecholamines has quite understandably aroused a great deal of interest. But there is now an almost compulsive desire to demonstrate, for all drugs which affect structures innervated by sympathetic nerve fibres, a drug effect in terms of uptake or storage or metabolism of adrenergic transmitter. However, this avenue of enquiry does not seem to have been very successful. In spite of a tremendous amount of work the way in which hypotension is brought about by drugs such as reserpine, guanethidine and methyldopa is still unknown. To begin with there is no real correlation between the pharmacological actions of these drugs and their effects on catecholamine stores.
Many workers have shown that guanethidine can reduce the noradrenaline content of peripheral tissues. However, significant depletion occurs only with large doses of guanethidine and even then only after two or more hours. In contrast, similar doses of guanethidine abolish the effects elicited by stimulation of sympathetic nerves within a few minutes. Moreover, Sanan & Vogt (1962) have found that in both rabbits and cats after even large doses of guanethidine (15-20 mg/kg) the loss of transmitter in sympathetic ganglia was too small and too slow to explain the failure of sympathetically innervated tissue to respond to electrical stimulation of its nerves; only about half of the ganglionic noradrenaline was lost in the course of two to four hours, a loss which is not sufficient to cause functional failure (Muscholl & Vogt 1958). Methyldopa is an inhibitor of DOPA-decarboxylase but the significance of this inhibition in the reduction of blood pressure is uncertain. There is experimental evidence also that after the administration of methyldopa the catecholamine content of the heart and other tissues decreases. However, there are great doubts as to the significance of catecholamine depletion in the hypotensive action of methyldopa. Finally, direct actions of the metabolites of methyldopa have been considered as an alternative explanation for the lowering of blood pressure but a variety of experimental results do not fit in with this 'false mediator' theory (for references see Pardo et a!. 1965) .
The powerful capacity of reserpine to deplete the heart and other tissues of their catecholamine content has often been proposed as the primary cause of its pharmacological actions. It is true that almost complete depletion can be caused by daily doses as small as 5 jg/kg. Nevertheless, as the doses are progressively increased beyond this level, or as they are extended in time, the myocardium and other tissues show ever more marked functional and histological changes. This interrelation of dose level and exposure period has been consistently evident throughout our studies based either on long-term administration of the drug to animals in doses approximate to those used in therapeutics or on short-tcr.rn treatment with larger doses (Zaimis 1964a, b) .
During the past few years, there has additionally developed a tendency to represent pharmacological effects of drugs such as reserpine, guanethidine and methyldopa as if they took place exclusively at the nerve endingin other words, as if the effector cells played a minor role or none at all. This approach is, to my mind, unrealistic. If a drug, by virtue of its chemical structure or other specific property, affects structures innervated by sympathetic nerves, it has as much chance of acting upon effector cells as upon the nerve endings, especially as most of these drugs penetrate cell membranes with ease.
Pharmacological studies at cholinergic synapses, our knowledge of which is much more complete than is that of adrenergic ones, have taught us that drugs produce, as a rule, a wealth of effects by acting on the effector cells themselves and that only very rarely do we come across drugs which act nowhere else than on the nerve ending. It is also useful to remember that both cardiac and smooth muscle show spontaneous rhythmic activity which is an intrinsic property of the muscle and is not due to external stimulation. Autonomic nerves, therefore, unlike motor nerves, are not essential for the contraction of either cardiac or smooth muscle. Local mechanisms become prominent after the normal nervous control is interrupted; a few weeks after the surgical removal of the sympathetic nervous system, the peripheral vessels regain a measure of control which permits rapid adaptation and fairly normal activity. This does not mean that the sympathetic nervous system is not important but indicates that additional mechanisms in the effector cells themselves can take over much of its function. One would, therefore, expect pharmacological actions which are restricted to the nerve endings to be more uniform and less severe than in fact are those produced by drugs such as reserpine, guanethidine and methyldopa.
The Immunosympathectomized Animal Levi-Montalcini and her co-workers (for references see Levi-Montalcini 1965) have shown that the growth and maintenance of sympathetic nerve cells is controlled by a specific protein referred to as the 'nerve growth factor' (NGF). Potent NGF, which is isolated at present from mouse salivary glands, injected into new-born animals causes a marked hypertrophy of the sympathetic ganglia. A second important discovery by the same group of workers was that the injection in new-born animals of an antiserum to the NGF results in the almost total destruction of their sympathetic ganglia. Immunosympathectomy (a term introduced by this group) thus offers the possibility of long-term experiments in animals deprived since birth of the peripheral sympathetic nervous system.
Using a generous supply of NGF-antiserum provided by Professors R Levi-Montalcini and P Angeletti, we were able to treat a reasonable number of new-born rats. This treatment resulted in almost complete destruction of the paravertebral ganglia and a 75% atrophy of the cmliac ganglion. Only the mesenteric ganglion escaped this massive destruction. The reduction in volume and in nerve cell density of the paravertebral ganglia was greater than 90 %. In the treated animals there was a good correlation between the degree of destruction of the sympathetic ganglia and the biochemical changes in tissues supplied with adrenergic neurones by these ganglia. For example, the noradrenaline content of the heart and spleen was almost zero, that of the small intestine was about 25 % while the noradrenaline content of the vas deferens was 65 % of that of the controls. In contrast, the total catecholamine levels in the adrenals did not differ significantly from those in the controls. Finally, these results correlated well with the loss of the capacity of various tissues to take up noradrenaline. In the treated animals, the uptake of 3H-noradrenaline was less than 14% of that of the controls in the heart, spleen, lungs and kidney; about 30% in the small intestine and colon, unchanged in the uterus and increased in the vas deferens (Zaimis et al. 1965) .
The body temperature of the immunosympathectomized rats was practically the same as that of the controls. Moreover, they were active, ate, drank, cleaned themselves and bred normally (Zaimis 1965 ). In the conscious treated rat the average blood pressure and heart rate were very similar to those ofthe untreated animals. After chloralose anesthesia, however, the average resting blood pressure, but not the heart rate, was lower in the immunosympathectomized rats. Finally the pressor as well as the positive inotropic responses to injected adrenaline and noradrenaline were significantly greater and more prolonged in the immunosympathectomized rat, while tyramine before, as well as after, bilateral adrenalectomy caused pressor responses comparable to those recorded in the controls. The essential feature of the tyramine action was an increase in heart rate significantly greater than that produced by adrenaline or noradrenaline.
In order to discover the extent to which the absence of sympathetic innervation modifies the effects produced by hypotensive drugs, immunosympathectomized and normal rats were treated with reserpine, guanethidine and methyldopa. In both groups of animals observations were made of: (1) The growth rate. (2) The resting blood pressure and heart rate. (3) The catecholamine content of the heart, spleen, intestine and adrenals. (4) The blood pressure and heart rate responses to intravenous adrenaline (30 ng), noradrenaline (30 ng) and tyramine (30 pig).
(1) The growth rate of both control and immunosympathectomized animals was not affected by either methyldopa or guanethidine. All the rats receiving reserpine, however, lost weight during the last two weeks of treatment and the percentage loss was almost the same for both control and immunosympathectomized animals.
(2) At the end of the chosen period the animals were anesthetized with chloralose, both vagi cut and their systemic blood pressure and heart rate recorded simultaneously on a Grass polygraph. In the guanethidine-and reserpine-treated normal and immunosympathectomized rats the resting heart rate and blood pressure decreased significantly. The heart rate decrease was almost the same in the two groups of animals. The overall decrease in blood pressure, however, was smaller in the immunosympathectomized animals possibly because their resting blood pressure, under anesthesia, is always lower than that of the normal rats. Treatment with methyldopa made little difference to the resting blood pressure and heart rate in either normal or immunosympathectomized rats.
(3) Assays of catecholamine content in peripheral tissues were carried out by my colleague, Mrs Lucienne Berk. The results showed that in the control animals guanethidine produced a marked reduction in the noradrenaline content of the heart, spleen and intestine and reserpine an almost total depletion. On the other hand, the overall reduction in the animals treated with methyldopa was only about 50%. Finally the catecholamine content of the adrenals in both normal and immunosympathectomized animals was little affected by any of the three drugs. (4) An overall comparison of changes in blood pressure and heart rate to adrenaline (30 ng), noradrenaline (30 ng) and tyramine (30 ,ug) in both control and immunosympathectomized animals showed that the responses to the three pressor agents were significantly altered by the reserpine, guanethidine and methyldopa treatment but that the recorded changes were very similar in both control and immunosympathectomized animals. For example, noradrenaline and especially adrenaline produced larger rises in blood pressure in all the animals treated with any of the three drugs. The pressor response to tyramine was significantly increased in the methyldopa-treated rats, both normal and immunosympathectomized. On the other hand, the chronotropic response to tyramine was increased in all the animals treated with guanethidine. A comparison between the groups of animals treated with saline and those with reserpine shows that in both normal and immunosympathectomized rats the pressor responses to adrenaline and noradrenaline were potentiated while those to tyramine remained the same or were slightly reduced.
From these results it is obvious that the peripheral adrenergic neurone is not the only point of attack of reserpine, guanethidine and methyldopa. The fact that the three hypotensive drugs produced very similar effects in both normal and immunosympathectomized animals strongly suggests a direct action on the effector cells themselves. So far I have put a negative point of view; merely demonstrating the inadequacy of current theories. At this point, I should like to justify myself by offering, however tentatively, something rather more positive. I would like to put forward the suggestion that compounds such as reserpine, guanethidine and methyldopa interfere primarily with metabolic pathways either in the adrenergic neurone or in the smooth muscle and the heart and that the catecholamine depletion is secondary to this primary biochemical lesion. If this suggestion proves valid, the discrepancies noted in the existing theories might be accounted for.
Metabolic Requirements of Sympathetic Neurones Larrabee & Bronk (1952) studied the metabolism of sympathetic neurones in vitro and in situ at rest and in action. The increase in rate of oxygen consumption at low frequencies of stimulation (e.g. 10/sec) was many times greater in sympathetic ganglia than in mammalian somatic nerve trunks. Subsequently it was found that the difference between ganglia and somatic nerves could be attributed, not to differences between cell bodies, dendrites and axons, but to important differences between sympathetic and somatic nervous tissues. This was indicated by the large increase in rate of oxygen consumption observed during activity in sympathetic nerve trunks. For example, percentage increases as great as those in ganglia were found in cervical sympathetic trunks excised from rabbits. This was true even when the stimuli were strong enough to excite only the B fibres, leaving at rest the many C fibres which are present in those nerves. Moreover, relatively enormous increases in oxygen uptake were found in inferior cardiac nerves (excised from cats) the fibres of which are almost entirely type C. Further experiments demonstrated that when glucose was withdrawn both the preganglionic and the postganglionic responses failed, the latter falling more rapidly. Larrabee & Bronk also showed that capacity for function can be lost in the absence of glucose, not only by intraganglionic structures, but also by axons of sympathetic nerve trunks and that this axonal failure can be greatly accelerated by activity.
It is well known that diguanidines are inhibitors of carbohydrate metabolism and that guanidine and especially some of its derivatives tend to lower the blood sugar level. Frank et al. (1926) tried one of the more effective derivatives, decamethylene diguanidine (Synthalin), as a hypoglycmmic agent in the treatment of diabetes. Is it not possible, therefore, that guanethidine, which after all is a guanidine (Fig 1) , interferes primarily with the carbohydrate metabolism of either the neurone or the effector cell or both and, in doing so, affects the normal function of the adrenergic neurone and of the effector cell itself?
The Mechanisms Involved in the Development of Tension by Smooth Muscle Mammalian smooth muscle when stimulated electrically or by drugs contracts and remains contracted as long as the stimulus lasts. Born (1956) produced evidence suggesting that the development of tension by smooth muscle involves two mechanisms. The first, responsible 3? for the immediate rise in tension which occurs when the muscle is stimulated, continues to function in anoxia and in the presence of 2:4dinitrophenol. The second mechanism, responsible for the sustained tension which the muscle shows both spontaneously and after stimulation, is abolished when metabolism is interfered with. For example, in the absence of glucose or of oxygen the smooth muscle contracts but its ability to sustain the increased tension is reduced or completely abolished.
Born also studied in the isolated tenia coli the effect of the absence of glucose and the effects of anoxia on the concentration of adenosine triphosphate (ATP) and creatine phosphate and found that while there is little or no decrease in the concentration of ATP that of creatine phosphate decreases considerably. Moreover, he showed that in the absence of glucose or of oxygen the active tension is correlated with the creatine phosphate concentration of the muscle..
Throughout our work we have come across pharmacological effects which suggest that hypotensive drugs can interfere with the ability of the smooth muscle to sustain contraction. For example, ileum excised from guinea-pigs treated with methyldopa for four or more days contracted to acetylcholine but its ability to sustain the increased tension was reduced. Fig 2 illustrates an experiment in which the responses of ileum removed from untreated guinea-pigs were compared with those of ileum removed from guineapigs treated with methyldopa.
Vascular smooth muscle of cats treated with small doses of reserpine (5 ig/kg/day) for several months showed a similar phenomenon (Withrington 1964) . In these animals the effect of a slow continuous infusion of noradrenaline on peripheral blood flow was studied. Peripheral blood flow was measured by recording the venous outflow from a hind limb and the slow continuous infusion of noradrenaline was administered close-arterially by means of a small cannula tied into the cut end of the artery supplying the gracilis muscle. The results showed that vaso- (5pg/kg/day for seven months). Between the markers, close-arterial infusion of noradrenaline (065g/min) constriction was not well maintained in the reserpine-treated cats. In the untreated animals, noradrenaline produced a marked decrease in blood flow which was well maintained throughout the period ofinfusion. In contrast, in the reserpinetreated cats blood flow decreased only at the beginning of the infusion and then, while the infusion was still going on, it gradually returned to the control level (Fig 3) . These results suggest a direct action of these drugs on the smooth muscle and the possibility that the defect could be the result of a disturbance in the normal supply of chemical energy to the muscle. Clearly a great deal of work remains to be done before these hypotheses are proved right or wrong. All I can say at this stage is that this seems a worth-while line to follow not only because it may lead us to a better understanding of the mode of action of hypotensive drugs but because it may throw some light on the changes occurring in arterial smooth muscle in hypertension.
